Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 23;13:1009. doi: 10.1038/s41467-022-28515-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A Cell viability of MM.1S cells treated 96 h with pomalidomide (pom), palbociclib (palb), or in combination. (N = 3 biologically independent replicates). B Synergy map of MM.1S cells treated with palbociclib in combination with lenalidomide or pomalidomide. C Cell viability of L363 cells treated with pomalidomide, palbociclib, or in combination (N = 3 biologically independent replicates). D Synergy map of L363 cells treated with palbociclib in combination with lenalidomide or pomalidomide. E Cell viability of MM.1S LenR cells (N = 3 biologically independent replicates) and F OPM2 CDK6 OE cells upon combination treatment of pomalidomide and palbociclib (N = 3 biologically independent replicates) Synergy levels are indicated with ZIP synergy scores. Synergy maps were generated with SynergyFinder⁷⁵. Cell viability is normalized to respective DMSO conditions. Data represent the mean ± SD of biological triplicates. One-way ANOVA is applied. P values are displayed as follows: n.s. = P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. Source data are provided as a Source Data file.